Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230893 · ClinicalTrials.gov registry record
Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years
A clinical trial, sponsored by Tuscaloosa Research & Education Advancement Corporation.
- Completed
- Registry status
- 99
- Enrollment target
NCT00230893: Completed study, sponsored by Tuscaloosa Research & Education Advancement Corporation.
NCT00230893 is a clinical trial that has completed, run by Tuscaloosa Research & Education Advancement Corporation. The registered enrollment target is 99 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00230893 has completed, sponsored by Tuscaloosa Research & Education Advancement Corporation.
- COMPLETED
- Registry status
- 99 participants
- Enrollment target
Study Summary
The primary objective is to examine the percentage of patients with PTSD who were prescribed an antipsychotic over the past seven years in the VA Network 7 (AL, GA, SC) and compare the percentage on an annual basis. We will also determine the type and dose of antipsychotics received. We hypothesize that there has been a significant increase in antipsychotic use, especially atypical antipsychotics, prescribed for patients with PTSD over the last 7 years
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2005-07 |
| Est. Completion | 2005-09 |
What the finished NCT00230893 record still lists
NCT00230893 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 99 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00230893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00230893 about?
NCT00230893 is a clinical study titled "Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years". The primary objective is to examine the percentage of patients with PTSD who were prescribed an antipsychotic over the past seven years in the VA Network 7 (AL, GA, SC) and compare the percentage on an annual basis. We will also determine the type and dose of antipsychotics received. We hypothesize ...
What is the current status of trial NCT00230893?
This trial is currently completed. The enrollment target is 99 participants. The study started on 2005-07. Estimated completion is 2005-09.
Who is sponsoring clinical trial NCT00230893?
This trial is sponsored by Tuscaloosa Research & Education Advancement Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia